AstraZeneca and UCL to collaborate on two immuno-oncology projects
4th February 2021
British drugmaker and researchers from the UCL Division of Infection & Immunity will collaborate on two projects which will aim to contribute to the development of new cancer treatments.
The new research collaborations will investigate immune checkpoints – key biochemical pathways that regulate the body’s immune responses.
Although immune checkpoints help to keep the body’s immune response at normal levels by not harming healthy cells, they can also block specialist immune cells from attacking and destroying cancer cells.
Over the last decade, the emergence of checkpoint inhibitor drugs have revolutionised cancer treatment and demonstrated benefit in clinical results for patients with solid tumours.